SCHEMBL30294684

SCHEMBL30294684

COC(=O)c1cc(C(F)(F)F)ccc1Nc1ccc(OC(F)(F)F)cc1C

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CFTR P13569 1/20 0.48
▸ TAS2R14 Q9NYV8 1/20 0.45
▸ DHODH Q02127 1/20 0.42
▸ SCN8A Q9UQD0 2/20 0.41
▸ SCN10A Q9Y5Y9 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ TRPV1 Q8NER1 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ P2RX7 Q99572 5/20 0.40
▸ PPARD Q03181 1/20 0.39
▸ IGF2BP2 Q9Y6M1 1/20 0.39
▸ AKR1C3 P42330 1/20 0.39
▸ AKR1C2 P52895 1/20 0.39
▸ CES2 O00748 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852810 1.00 CFTR (0.48) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL30294511 0.91 DHODH (0.49) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL22853395 0.91 DHODH (0.49) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL22853416 0.91 CFTR (0.46) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL30294604 0.91 CFTR (0.46) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL30294428 0.90 TAS2R14 (0.54) TAS2R14DHODHIGF2BP2AKR1C3AKR1C2
SCHEMBL22852849 0.90 TAS2R14 (0.54) TAS2R14DHODHIGF2BP2AKR1C3AKR1C2
SCHEMBL22833864 0.85 CFTR (0.50) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL29383454 0.85 CFTR (0.50) CFTRTAS2R14DHODHSCN8ASCN10A
SCHEMBL22853393 0.83 DHODH (0.46) CFTRDHODHP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B CFTR 402/4885TAS2R14 1406/4885DHODH 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback